PET/CT imaging for prostate cancer patients becomes more accurate and available
RSU Nuclear medicine clinic offers more accurate and available PSMA PET/CT scan for prostate cancer patients using new radiopharmaceutical ¹⁸F-PSMA.
The new radiopharmaceutical ¹⁸F-PSMA is alternative to ⁶⁸Ga-PSMA-11 and has been developed and implemented in cooperation with the Center of Nuclear Medicine, Radiology Research Laboratory Riga Stradins University, and leading foreign radiology research centers and clinics. The new radiopharmaceutical is more sensitive at lower PSA levels, which guaranties even more accurate detection of prostate cancer.
